A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 213
- Registration Number
- NCT03234972
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Peking Union Medical College Hospital, Beijing, China
🇨🇳Peking University First Hospital, Beijing, China
A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 39
- Registration Number
- NCT03235219
- Locations
- 🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸ProSciento, Inc., Chula Vista, California, United States
A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 287
- Registration Number
- NCT03227224
- Locations
- 🇷🇺
Engels psychiatric hospital, Saratov Region, Russian Federation
🇷🇺Clinical Psychiatry Hospital n.a. N.N. Solodovnikov, Omsk, Russian Federation
🇷🇺City Psychiatric Hospital of St. Nikolay Chudotvorets, Saint-Petersburg, Russian Federation
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 220
- Registration Number
- NCT03217812
- Locations
- 🇭🇰
Queen Mary Hospital University of Hong Kong, Hong Kong, Hong Kong
🇰🇷Ulsan University Hospital, Ulsan, Korea, Republic of
🇲🇾Hospital Ampang, Ampang, Malaysia
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
- Conditions
- Amyloidosis
- Interventions
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 416
- Registration Number
- NCT03201965
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 147
- Registration Number
- NCT03185819
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Federico II, Napoli, Italy
🇫🇷Hopital Sainte Anne, Paris, France
🇮🇹OSP RIUNITI-DIP Donna- Bambino, Foggia, Italy
A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: JNJ-64140284 150 mgDrug: JNJ-64140284 10 mgDrug: JNJ-64140284 0.5 mgDrug: JNJ-64140284 50 mgDrug: JNJ-64140284 (dose to be determined [TBD])Drug: JNJ-64140284 0.1 mgDrug: JNJ-64140284 2.5 mgDrug: Placebo
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT03180762
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 171
- Registration Number
- NCT03170518
- Locations
- 🇨🇳
Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
🇺🇸Arkansas Childrens Hospital, Little Rock, Arkansas, United States
🇺🇸Center of Excellence for Diabetes and Endocrinology (CEDE), Sacramento, California, United States
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 383
- Registration Number
- NCT03162796
- Locations
- 🇵🇱
Centrum Medyczne Hetmańska, Poznań, Poland
🇵🇱Etyka Osrodek Badan Klinicznych, Olsztyn, Poland
🇵🇱Nasz Lekarz Przychodnie Medyczne, Torun, Poland
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 741
- Registration Number
- NCT03158285
- Locations
- 🇱🇹
Siauliai Republican Hospital, Public Institution, Siauliai, Lithuania
🇵🇱Centrum Badań Klinicznych PI-House sp. z o.o., Gdansk, Poland
🇺🇦Mi 'Kherson City Clinical Hospital Of E.E. Karabelesh', Kherson, Ukraine